Palivizumab

Item number	Size	Delivery time	Price
TGM-T76907-1mg	1 mg	7 - 10 business days*	215.00€
TGM-T76907-5mg	5 mg	7 - 10 business days*	546.00€
TGM-T76907-10mg	10 mg	7 - 10 business days*	781.00€
TGM-T76907-25mg	25 mg	7 - 10 business days*	1,156.00€
TGM-T76907-50mg	50 mg	7 - 10 business days*	1,564.00€
TGM-T76907-100mg	100 mg	7 - 10 business days*	2,114.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that... more

Close menu

Product information "Palivizumab"

Description: Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV). Target: RSV. References: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998 Sep,102(3 Pt 1):531-7.

Keywords:	MEDI 493, Synagis
Supplier:	TargetMol
Supplier-Nr:	T76907

Properties

Application:	Targets Pneumoviridae fusion glycoprotein F0 (F)
Conjugate:	No

Database Information

CAS :	188039-54-5\| Matching products
KEGG ID :	K19261 \| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "Palivizumab"

Write a review